According to UnivDatos, rising global awareness and diagnosis of women’s health issues, increasing adoption of digital health platforms, coupled with rising mergers and acquisitions, are the major factors driving the growth of the premenstrual syndrome treatment market. As per their “Premenstrual Syndrome Treatment Market” report, the global market was valued at USD 1,951.79 million in 2024, growing at a CAGR of about 4.74% during the forecast period from 2025 – 2033 to reach USD million by 2033.

Premenstrual syndrome (PMS) is a health issue that involves physical and psychological symptoms occurring about five days before menstruation and ending a few days after it begins. The most common symptoms are appetite changes, breast tenderness, abdominal pain, back pain, headache, fatigue, insomnia, depressive affect, irritability, angry outbursts, and anxiety. Some women encounter mild discomfort, whereas others experience major disruptions in their daily routines. The condition is related to hormonal changes, serotonin levels, and lifestyle changes such as stress and diet.

Increasing Adoption of Digital Health Platforms for Symptom Tracking and Personalized Care

The increasing adoption of digital health platforms for symptom tracking and personalized care is a significant trend in the PMS market. The rising advancement in women’s health technology, such as mobile apps, wearable devices, and AI-driven platforms, allows women to monitor, understand, and manage their menstrual health. In addition, these AI platforms collect data, analyze it, and produce tailored reports and recommendations, facilitating more precise treatments and strengthening communication between doctors and patients. Such an approach not only increases adherence to treatment plans but also promotes preventive care by detecting early signs of hormonal imbalances or PMS-related issues. Digital health tools are especially popular among younger, tech-savvy users due to their convenience. Furthermore, different apps now connect with telehealth services, allowing women to directly consult gynecologists, nutritionists, or mental health experts via their smartphones. For instance, in 2024, Flo Health added an AI-based PMS management feature to its menstrual tracking app. The platform employs machine learning to forecast PMS onset, suggest lifestyle adjustments, and connect users with tailored supplements or medication plans.

Access sample report (including graphs, charts, and figures) – https://univdatos.com/reports/premenstrual-syndrome-treatment-market?popup=report-enquiry

Investments and Strategic Acquisitions Fuel Growth in the Global Premenstrual Syndrome Treatment Market

Major industry players are investing heavily in research and development in the premenstrual syndrome treatment market, improving focus on expanding their women’s health portfolios, and accelerating the commercialization of novel therapies. These investments concentrate on researching and producing advanced PMS treatment remedies and neurohormonal and psychotropic drugs. One of the major types of investments is continuous mergers and acquisitions (M&A), as they allow industries to grow geographically, diversify their product portfolio, and improve supply chains. For instance, in February 2025, Asarina Pharma AB sold its compound Sepranolone (UC1010), which is used for treating PMDD and severe PMS, to Relmada Therapeutics Inc. With these moves, Relmada strengthens its neuroactive steroid along with its women’s healthcare portfolio. Such moves help in increasing market share and improving the product portfolio, operational efficiency, and long-term competitiveness in the global premenstrual syndrome treatment market.

Strategic Acquisitions and AI Integration Driving Growth of Global Premenstrual Syndrome Treatment Market

The premenstrual syndrome treatment market is set to grow steadily, due to continuous investment and technological innovation. Strategic investments also play an important role in improving the product portfolio, ensuring the availability of products, and improving the integration of the value chain. The growing integration of AI-based platforms is improving the women’s healthcare product portfolio. Additionally, as partnerships, mergers, and acquisitions rise, companies are expected to improve operational efficiency and long-term competitiveness in the global premenstrual syndrome treatment industry.

Contact Us:

UnivDatos

Email – contact@univdatos.com

Website – www.univdatos.com